In the long journey of cancer treatment technology development, we have been pursuing a “magic bullet” that can accurately identify and eliminate cancer cells while sparing normal cells.ADC drugs—Antibody-Drug Conjugates—are a new therapeutic approach that comes close to this ideal. In recent years,ADC drugs have achieved remarkable success in the field of tumor treatment, with … Read more
Introduction The emergence of dual payload antibody-drug conjugates (ADCs) and peptide-drug conjugates (PDCs) marks a significant evolution in the field of targeted therapy. 01 Background Antibody-drug conjugates (ADCs) have garnered attention for their ability to deliver cytotoxic agents precisely to cancer cells, earning them the title of “magic bullets” for tumor treatment.However, ADCs still face … Read more
Antibody-drug conjugates (ADCs) have emerged as a significant platform for precision oncology, demonstrating remarkable efficacy in various solid tumors in recent years. With ongoing innovations in target selection and linker technology, the development of ADCs for the treatment of metastatic castration-resistant prostate cancer (mCRPC) has also made significant strides. This article systematically reviews the latest … Read more
When the dual-antibody ADC drug iza-bren presented an astonishing “objective response rate of 100%” at the 2025 World Lung Cancer Conference, this category of drugs, known as “biological missiles,” completely rewrote the narrative logic of tumor treatment. From the first approved drug, trastuzumab, to the domestically developed dual-antibody ADCs, ADC drugs have established a foothold … Read more
Click the arrow to follow us with the “blue text”! 1. 20ins Mutation: The ‘Hard-to-Treat Code’ of the EGFR Family The EGFR exon 20 insertion (20ins) mutation accounts for 4%-12% of NSCLC. Due to the unique mutation site, traditional EGFR-TKIs (such as gefitinib and osimertinib) struggle to bind effectively, leading to its classification as a … Read more
Professor Shen Lin’s team tackles gastric cancer! The CLDN18.2 targeted ADC drug IBI343 Phase I study tops Nature Medicine. Gastric cancer, as a “health killer” globally, is particularly rampant in East Asia. Data shows that in 2022, there were 358,700 new cases of gastric cancer in China, with 260,400 deaths, accounting for nearly 40% of … Read more
1. Research Background Ulcerative colitis (UC) is a chronic intestinal disease that severely affects the quality of life of patients and significantly increases the risk of colorectal cancer (CAC) associated with colitis, posing a major threat to patient survival. Current treatment strategies for UC are limited by single therapeutic mechanisms, uncontrolled drug release, and non-specific … Read more
On August 15, 2025, the journal Nature Communications published an article titled “A humanized anaplastic lymphoma kinase (ALK)-directed antibody-drug conjugate with pyrrolobenzodiazepine payload demonstrates efficacy in ALK-expressing cancers” (靶向间变性淋巴瘤激酶（ALK）的人源化抗体药物偶联物搭载吡咯并苯二氮䓬有效载荷在ALK表达癌症中的疗效验证).This study developed a novel ALK-targeted antibody-drug conjugate CDX0239-PBD, which demonstrates significant anti-tumor activity and survival benefits in various ALK-expressing pediatric and adult tumor models (including neuroblastoma, … Read more
The standard treatment (SoC) for surgically resectable early-stage (I-IIIB) NSCLC patients is surgery combined with (new) adjuvant systemic therapy for patients with stage II to IIIB and certain stage IB patients, with chemotherapy and radiotherapy used in select cases (for stage III disease with mediastinal lymph node metastasis). Despite these treatments, metastatic recurrence is common … Read more
Introduction Antibody-drug conjugates (ADC) therapy has rapidly developed over the past few decades, with 14 products approved globally and over 140 ADCs currently in clinical trials. By 2030, the ADC market is expected to exceed $15 billion. The basic principle of ADCs is that by combining the specificity of monoclonal antibodies with the cytotoxicity of … Read more